Feruloyl coenzyme A 6 '-hydroxylase pocket mutant and application thereof
By designing the feruloyl Coenzyme A 6'-hydroxylase pocket mutant, the problem of low biosynthesis of scopolamine was solved, and the efficient biosynthesis of coumarin compounds was achieved, especially with a simple carbon source as the source , efficient synthesis of re-start, significantly improved output, suitable for industrial production.
Patent Information
- Application Number
- CN202410968135.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-18
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-07-18
AI Technical Summary
In the prior art, the biosynthesis yield of scopolin is low, which limits the efficient synthesis of coumarin compounds.
By designing the feruloyl Coenzyme A 6'-hydroxylase pocket mutant, the enzyme activity is improved, and the application of this mutant in biosynthetic coumarin compounds can be used to achieve efficient synthesis of scopolamine, quintolin, quintolin, etc. Compounds, especially those produced from simple carbon sources, are highly efficiently synthesized from the source.
The yield of scopolamine has been significantly improved, and the efficient biosynthesis of coumarin compounds has been achieved, with the output increased by more than 3.2 times, reducing production costs, and providing a basis for industrial production.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedical engineering, and in particular relates to a feruloyl-CoA 6'-hydroxylase pocket mutant and application thereof. Background Art
[0002] Coumarin is an important class of organic heterocyclic compounds with benzopyrone as the basic nucleus, which plays an important physiological role in plant secondary metabolism. Coumarin has diverse structures and a wide range of pharmacological activities, including antibacterial, anti-inflammatory, central nervous system excitation and anticoagulation. It is an important raw material in the fields of medicine, food and cosmetics. Therefore, coumarin compounds have always been a research hotspot in the field of biomedicine at home and abroad.
[0003] In the metabolism of plants and bacteria, the carbon source can be converted into L-tyrosine through the shikimic acid metabolic pathway. L-tyrosine is converted into p-coumaric acid (p-CA) by tyrosine ammonia lyase (TAL), p-coumaric acid is converted into caffeic acid (CA) by flavin reductase (Fre) and p-hydroxyphenylacetic acid-3-hydroxylase (HpaBC), caffeic acid is converted into ferulic acid by caffeic acid methoxytransferase (COMT), and ferulic acid (FA) is converted into 6-hydroxyferuloyl-CoA by p-coumaryl-CoA ligase (4CL) and feruloyl-CoA 6'-hydroxylase (F6'H), which is then converted into scopoletin by coumarin synthase (COSY) or spontaneous isomerization. Scopolamine can be synthesized into various high value-added coumarin compounds through a series of derivatization reactions, such as hydroxylation, glycosylation and isopentenylation. For example, BASF et al. disclosed coumarin synthesis and its use (COUMARIN SYNTHESIS AND USESTHEREOF) in WO2023156270A1 applied for on February 8, 2023. The patent application discloses the biosynthetic pathway of coumarin compounds such as scopolamine, quercetin, and quercetin. Therefore, scopolamine is an important platform compound in the synthesis of coumarin compounds and is the key to the synthesis of other coumarin compounds. However, there are problems such as low biosynthesis yield of scopolamine in the prior art. Summary of the invention
[0004] According to research, feruloyl-CoA 6'-hydroxylase (F6'H) is the rate-limiting enzyme for the biosynthesis of coumarin compounds. Therefore, one of the main purposes of the present invention is to provide a feruloyl-CoA 6'-hydroxylase pocket mutant, which can improve the enzyme activity and is conducive to effectively increasing the yield of biosynthetic coumarin compounds without affecting the growth of the bacteria.
[0005] The second main purpose of the present invention is to utilize the above-mentioned feruloyl-CoA 6'-hydroxylase pocket mutant in the biosynthesis of coumarin compounds, such as scopoletin, fraxin, and fraxinoside, which is conducive to the efficient biosynthesis of coumarin compounds, especially to achieve efficient de novo synthesis of coumarin compounds with a simple carbon source as the source. Wherein, the "simple carbon source" in the present invention refers to a monosaccharide, a disaccharide or any combination thereof.
[0006] Specifically, the technical solution provided by the present invention is as follows:
[0007] A feruloyl-CoA 6'-hydroxylase (F6'H) pocket mutant is mainly obtained by amino acid mutation of the amino acid sequence shown in SEQ ID NO.1, including at least one of the following amino acid mutations: L141N, Q144D, and N311G. Among them, the mutant L141N represents that the leucine at position 141 is mutated to asparagine, the mutant Q144D represents that the glutamine at position 144 is mutated to aspartic acid, and the mutant N311G represents that the asparagine at position 311 is mutated to glycine.
[0008] The amino acid mutation may be a single mutation, a double mutation or a triple mutation. Preferably, the amino acid mutation is a double mutation or a triple mutation. Preferably, the feruloyl-CoA 6'-hydroxylase pocket mutant may be a L141N-Q144D double mutant or a L141N-Q144D-N311G triple mutant. Wherein, the L141N-Q144D double mutant is a double mutant in which L141N and Q144D are mutated simultaneously, which represents that the leucine at position 141 is mutated to asparagine, and the glutamine at position 144 is mutated to aspartic acid. The L141N-Q144D-N311G triple mutant is a triple mutant in which L141N, Q144D and N311G are mutated simultaneously, which represents that the leucine at position 141 is mutated to asparagine, and the glutamine at position 144 is mutated to aspartic acid, and the asparagine at position 311 is mutated to glycine.
[0009] The feruloyl-CoA 6'-hydroxylase (F6'H) is derived from Arabidopsis thaliana.
[0010] The method for obtaining the above-mentioned feruloyl-CoA 6'-hydroxylase mutant specifically comprises: designing a feruloyl-CoA 6'-hydroxylase gene mutant library by combining molecular docking methods; introducing enzymes required for the biosynthesis pathway of coumarin compounds into host bacteria, selecting suitable transformants for testing, and selecting the feruloyl-CoA 6'-hydroxylase mutant with the best effect.
[0011] A gene encoding the above-mentioned feruloyl-CoA 6'-hydroxylase (F6'H) pocket mutant.
[0012] A recombinant plasmid, the recombinant plasmid is connected with the above gene. Preferably, the plasmid includes but is not limited to pZE12-luc, pCS27 or pSA74.
[0013] An application of the above-mentioned feruloyl-CoA 6'-hydroxylase pocket mutant in the biosynthesis of coumarin compounds, wherein the coumarin compounds may be scopoletin, scopolamine, fraxinin, fraxinin and the like.
[0014] An engineered bacterium for synthesizing coumarin compounds, comprising a host bacterium and the above-mentioned recombinant plasmid transformed into the host bacterium. Wherein, the host bacterium is a non-plant cell. Preferably, the host bacterium is an original or modified bacterium, or an original or modified fungus; for example, original or modified Escherichia coli, Bacillus subtilis, Corynebacterium glutamicum, Saccharomyces cerevisiae or Pichia pastoris, etc. More preferably, the host bacterium can be Escherichia coli BW25113; further more preferably, the Escherichia coli is BW25113ΔpykA / F::aroG fbr ::tyrA fbr ; In this way, pyruvate kinase pykA / F was knocked out, and the feedback inhibition of 2-dehydro-3-deoxyheptanoic acid phosphoenolase AroG was relieved. fbr and chorismate mutase / prephenate dehydrogenase TyrA fbr , which can increase the yield of tyrosine synthesized by the shikimic acid pathway, thereby enhancing the upstream pathway to increase the yield of coumarin compounds synthesized from scratch by engineered bacteria that synthesize coumarin compounds.
[0015] The recombinant plasmid is also connected with genes encoding tyrosine ammonia lyase (TAL), flavin reductase (Fre), p-hydroxyphenylacetic acid-3-hydroxylase (HpaBC), caffeic acid methoxytransferase (COMT) and p-coumaryl-CoA ligase (4CL). In this way, the engineered bacteria is a 6-hydroxyferuloyl-CoA synthesis engineered bacteria, which can achieve efficient synthesis of 6-hydroxyferuloyl-CoA; in particular, it can achieve efficient synthesis of 6-hydroxyferuloyl-CoA from scratch with a simple carbon source as the source; and it can also construct a synthesis engineered bacteria for coumarin compounds such as scopoletin, scopoletin, fraxinin, and fraxinin with the 6-hydroxyferuloyl-CoA synthesis engineered bacteria as the starting bacteria.
[0016] Furthermore, the recombinant plasmid is also connected with a gene encoding coumarin synthase (COSY), so that the engineered bacteria is a scopolamine synthesis engineered bacteria, which can achieve efficient synthesis of scopolamine; in particular, it can achieve efficient synthesis of scopolamine from scratch with a simple carbon source as the source. In addition, the scopolamine synthesis engineered bacteria can also be used as the starting bacteria to construct an engineered bacteria for the synthesis of coumarin compounds such as scopolamine, fraxinin, and fraxinin.
[0017] Furthermore, the recombinant plasmid is also connected with a gene encoding scopolamine-glycosyltransferase. Thus, the engineered bacteria is a scopolamine synthesis engineered bacteria, which can achieve efficient synthesis of scopolamine; in particular, it can achieve efficient synthesis of scopolamine from scratch using a simple carbon source as the source.
[0018] Furthermore, the recombinant plasmid is also connected with a gene encoding scopoletin-8-hydroxylase (S8H), so that the engineered bacteria is a quercetin synthesis engineered bacteria, which can achieve efficient synthesis of quercetin; in particular, it can achieve efficient synthesis of quercetin from scratch with a simple carbon source as the source. In addition, the quercetin synthesis engineered bacteria can also be used as the starting bacteria to construct an engineered bacteria for the synthesis of coumarin compounds such as quercetin.
[0019] Furthermore, the recombinant plasmid is also connected to a gene encoding quercetin-8-O-glycosyltransferase, so that the engineered bacteria is a quercetin-synthesizing engineered bacteria, which can achieve efficient synthesis of quercetin; in particular, it can achieve efficient synthesis of quercetin from scratch using a simple carbon source as the source.
[0020] In the present invention, the tyrosine ammonia lyase (TAL) is preferably derived from Rhodobacter sphaeroides, Rhodobacter glutinis, Streptomyces albus, Rhodobacter capsulatus or Micromonospora echinofusca, etc.; the p-coumaroyl-CoA ligase (4CL) is preferably derived from Arabidopsis thaliana or Petroselinum crispum, etc. The flavin reductase (Fre) is derived from Escherichia coli, the p-hydroxyphenylacetic acid-3-hydroxylase (HpaBC) is derived from Klebsiella pneumonia, and the caffeic acid methoxytransferase (COMT) is derived from Arabidopsis thaliana. The coumarin synthase (COSY) is derived from Arabidopsis thaliana, Solanum tuberosum or Glycine max, etc. The scopoletin-8-hydroxylase (S8H) is derived from Arabidopsis thaliana. The quercetin-8-O-glycosyltransferase UGT71E is derived from Arabidopsis thaliana, and can be UGT71E1, UGT71E2, or UGT71E3. The scopoletin-glycosyltransferase GT is derived from Nicotiana tabacum or Arabidopsis thaliana, and can be a 7-O-glycosyltransferase or an 8-O-glycosyltransferase, such as TOGT1, TOGT2, UGT71E1, UGT71E2, or UGT71E3.
[0021] A method for biosynthesizing coumarin compounds, comprising: inoculating the engineered bacteria for synthesizing coumarin compounds into a fermentation medium at an inoculation volume of 1% to 10% for fermentation to obtain coumarin compounds. The inoculation volume is preferably 2% to 5%; the fermentation temperature is preferably 30°C to 40°C for fermentation; the fermentation medium preferably includes: 0.5 to 1.5 g / L FeSO 4 , 1~5g / L MOPS, 5~20g / L carbon source, 1~5g / L yeast powder, 5~8g / L Na 2 HPO 4 , 0.3~2g / L NaCl, 2.3~4.0g / L KH 2 PO 4 and 1-5 g / L NH 4Cl.
[0022] The carbon source in the fermentation medium is a monosaccharide, a disaccharide or any combination thereof. Preferably, the carbon source in the fermentation medium is one or any combination of glycerol, glucose, sucrose, fructose and xylose. In the fermentation culture process, 0.25-1 mM of the inducer IPTG is added.
[0023] Furthermore, the above-mentioned synthesis method also includes the step of first adding an intermediate compound to the fermentation medium and then fermenting and culturing the engineered bacteria; wherein the intermediate compound is an intermediate on the path of synthesizing the target compound, preferably at least one of tyrosine, p-coumaric acid, caffeic acid, ferulic acid, scopoletin and fraxin. For example, scopoletin or fraxin is added to the fermentation medium so as to achieve the in vitro addition of scopoletin to synthesize scopoletin or fraxin, or to achieve the in vitro addition of fraxin to synthesize fraxinoside.
[0024] Therefore, the feruloyl-CoA 6'-hydroxylase pocket mutant provided by the present invention is obtained by mutating the wild-type feruloyl-CoA 6'-hydroxylase through the site-directed saturation mutagenesis technique, and can improve the activity of feruloyl-CoA 6'-hydroxylase. According to the test, the yield of scopoletin synthesized by the feruloyl-CoA 6'-hydroxylase mutant can be increased by more than 3.2 times, and even 13.9 times, compared with the yield of scopoletin synthesized by the wild-type feruloyl-CoA 6'-hydroxylase.
[0025] Furthermore, the production of coumarin compounds using the engineered bacteria containing the feruloyl-CoA 6'-hydroxylase pocket mutant encoding gene provided by the present invention has the advantages of high yield and a wide variety of species, is conducive to industrialized scale-up production, reduces production costs, and provides an important basis for the industrial production of coumarin compounds.
[0026] Furthermore, the present invention utilizes the above-mentioned feruloyl-CoA 6'-hydroxylase pocket mutant to realize for the first time the efficient de novo biosynthesis of scopoletin, quercetin, quercetin and scopolamine using a simple carbon source as the source, with the yields of 43.2 mg / L, 52.2 mg / L, 115.7 mg / L and 82.9 mg / L, respectively. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 It is a schematic diagram of the production pathway of scopoletin, quercetin, quercetin and scopolamine using genetically engineered bacteria;
[0028] Figure 2 This is a comparison chart of the yield of scopoletin synthesized by using scopoletin synthesis engineering bacteria and its mutants in Example 3 of the present invention, wherein the mutants of scopoletin synthesis engineering bacteria use single mutants, double mutants and multiple mutants of feruloyl-CoA 6'-hydroxylase;
[0029] Figure 3 This is a diagram showing the fermentation results of synthesizing quercetin under different COSY conditions using the quercetin synthesis mutant engineering bacteria BW3' in Example 4 of the present invention;
[0030] Figure 4 This is a diagram showing the fermentation result of synthesizing frasin using the frasin synthesis mutant engineering bacteria BW30' in Example 4 of the present invention;
[0031] Figure 5 This is a diagram showing the fermentation results of synthesizing fraxinoside using the fraxinoside synthesis mutant engineering bacteria BW4' under different fraxinoside-8-O-glycosyltransferase conditions in Example 5 of the present invention;
[0032] Figure 6 This is a diagram showing the fermentation result of synthesizing fraxinoside using the fraxinoside synthesizing mutant engineered bacteria BW40' in Example 5 of the present invention;
[0033] Figure 7 This is a diagram showing the fermentation results of synthesizing scopoletin using the scopoletin synthesis mutant engineering bacteria BW5' under different scopoletin-glycosyltransferase conditions in an embodiment of the present invention;
[0034] Figure 8 This is a diagram of the fermentation results of synthesizing scopoletin using the scopoletin synthesis mutant engineering bacteria BW50' in an embodiment of the present invention.
[0035] In the sequence list:
[0036] SEQ ID NO.1 is the amino acid sequence of wild-type feruloyl-CoA 6'-hydroxylase F6'H;
[0037] SEQ ID NO.2 is the nucleotide sequence shown by primer L141N-F;
[0038] SEQ ID NO.3 is the nucleotide sequence shown by primer L141N-R;
[0039] SEQ ID NO.4 is the nucleotide sequence shown by primer Q144D-F;
[0040] SEQ ID NO.5 is the nucleotide sequence shown by primer Q144D-R;
[0041] SEQ ID NO.6 is the nucleotide sequence shown by primer N311G-F;
[0042] SEQ ID NO.7 is the nucleotide sequence shown by primer N311G-R. DETAILED DESCRIPTION
[0043] The technical solution of the present invention is further described in detail below through specific implementation methods. In the present invention, there is no special requirement for the type of expression plasmid. It can be considered that the construction method for expressing the target gene in Escherichia coli can adopt various methods commonly used in the art, such as connecting the target gene to the vector after enzyme digestion, replacing the promoter, knocking out the gene method, gene mutation method, etc., which will not be repeated hereafter.
[0044] 1) Enzymes used in the examples
[0045] The various enzymes involved in the present invention are all derived from commonly used substances, and the sources of the enzymes are not limited to those listed in the present invention. As long as the similarity with the enzymes listed in the present invention is within 80%, they are within the protection scope of the present invention. In the following examples and comparative examples, in addition to the key enzymes shown in Table 1, other enzymes such as various enzymes used in the pathway for synthesizing shikimic acid from carbon sources are also existing commonly used enzymes.
[0046] Table 1 Enzymes used in various examples and comparative examples
[0047]
[0048]
[0049] 2) E. coli related test steps
[0050] E. coli transformation, plasmid extraction, DNA gel recovery, and DNA fragment ligation were all performed according to the instructions of the corresponding kits.
[0051] The transformed E. coli clones were identified by plasmid PCR. A single colony was picked from the plate and inoculated into a test tube. After plasmid extraction, 2× Taq Plus Master Mix II DNA polymerase was used to perform plasmid PCR verification, and the cloned segment was identified by DNA sequencing. The E. coli colony PCR amplification system and reaction conditions are shown in Table 2.
[0052] Table 2 Escherichia coli colony PCR amplification system and reaction conditions
[0053]
[0054] 3) Preparation and transformation of E. coli competent cells
[0055] Streak the host strain stored in the glycerol tube on a non-resistant LB plate and place it in a 37°C constant temperature incubator overnight. Inoculate the single colony grown on the plate into 4 mL LB non-resistant liquid medium and culture it in a constant temperature shaker at 37°C, 220 rpm overnight. Transfer the seed liquid strain in the test tube to 50 mL LB liquid medium and culture it at 37°C, 220 rpm for 1.5-2 hours until the OD600 Reach about 0.4-0.6. Pour the bacterial solution into a sterilized 50mL centrifuge tube, centrifuge at 5000rpm for 5min at 4℃, remove the supernatant and collect the bacteria. Add 20mL of sterilized 10% glycerol to the centrifuge tube, wash away the residual culture medium, centrifuge at 5000rpm for 5min at 4℃, and repeat this operation twice. Add 500μL of sterilized 10% glycerol to resuspend the bacteria, divide into 100μL per tube for transformation. Take a clean 1mm electroporation cup, place it on ice for later use, add the plasmid to be transformed to the competent state, gently blow and mix, and add it to the electroporation cup; turn on the electroporator, set the transformation mode, push the electroporation cup with the mixed solution between the two electrodes, and perform electric shock. After the electroporation, add 600 μL of LB sterile medium to the electroporation cup, gently blow and mix to fully mix the bacterial solution and the medium, then transfer to a 1.5 mL centrifuge tube and place in a 37°C constant temperature incubator to recover for 45-60 minutes. Take 100 μL of the recombinant strain and evenly spread it on a selective solid medium with the corresponding antibiotics, and place it in a 37°C constant temperature incubator overnight to culture a single colony.
[0056] 4) Culture medium used in the embodiment
[0057] LB medium: yeast powder 5g / L, peptone 10g / L, sodium chloride 10g / L;
[0058] Fermentation medium used: 2g / L MOPS, 20g / L glycerol, 5g / L yeast powder, 6.78g / L Na 2 HPO 4 , 0.5g / LNaCl, 3g / L KH 2 PO 4 and 1 g / L NH 4 Cl;
[0059] 5) Plasmids and strains used in the examples
[0060] In the following examples, E. coli strains BW25113 and trans5α are both commonly used E. coli strains, both of which are commercially available, wherein trans5α is used for vector construction, and BW25113 is used as the initial host strain for constructing expression plasmids. The plasmids and strains used in each example are shown in Table 3.
[0061] Table 3 Plasmids mainly used in each embodiment and comparative example
[0062]
[0063]
[0064] Among them, the recombinant Escherichia coli BW1 in Table 3: BW25113ΔpykA / F::AroGfbr ::TyrA fbr This was mainly achieved by knocking out pyruvate kinase pykA / F and overexpressing the endogenous key enzyme AroG in the shikimate pathway. fbr 、TyrA fbr To enhance the supply of shikimic acid pathway, increase the production of tyrosine, and help increase the production of coumarin compounds. The construction method of strain BW1 mainly includes: firstly using the RED knockout method to knock out the gene pykA / F in the chromosome of Escherichia coli BW25113 to obtain Escherichia coli BW25113ΔpykA / F; then using the CRISPR-Cas9 recombination method to knock out aroG fbr 、TyrA fbr Integrated into the genome of Escherichia coli BW25113ΔpykA / F.
[0065] 6) Detection conditions of HPLC analysis adopted in the embodiment
[0066] a) In the embodiment, the conditions for detecting scopoletin, fraxin, fraxinoside and scopoletin standard products and fermentation products by HPLC analysis method are as follows:
[0067] Chromatographic column: Separation column: Diamonsil C18, ID 5 μm, 250 × 4.6 mm;
[0068] Mobile phase: A is methanol, B is 2‰ trifluoroacetic acid aqueous solution, column temperature is 40°C, flow rate is 1.0mL / min, and detection wavelength is 345nm. The gradient elution program is shown in Table 4 below:
[0069] Table 4 Gradient elution program
[0070] Time (min) Mobile phase A% Mobile phase B% 0 5 95 10 35 65 20 85 15 25 5 95
[0071] In the following examples, feruloyl-CoA 6'-hydroxylase was modified based on the feruloyl-CoA 6'-hydroxylase gene from Arabidopsis thaliana to obtain a feruloyl-CoA 6'-hydroxylase mutant with higher catalytic activity.
[0072] See also Figure 1The original carbon source is converted into tyrosine through the shikimic acid pathway, which is then converted into p-coumaric acid by tyrosine ammonia lyase TAL, which is then converted into caffeic acid (CA) by flavin reductase Fre and p-hydroxyphenylacetic acid-3-hydroxylase HpaBC, which is then converted into ferulic acid (FA) by caffeic acid methoxytransferase COMT, which is then converted into 6-hydroxyferuloyl-CoA by p-coumaryl-CoA ligase 4CL and feruloyl-CoA 6'-hydroxylase F6'H, and then into scopoletin by coumarin synthase COSY or spontaneous isomerization. Scopoletin is converted into quercetin by scopoletin-8-hydroxylase (S8H), and quercetin is converted into quercetin by quercetin-8-O-glycosyltransferase (UGT71E). Scopolamine can also be converted into scopolamine by scopolamine-glycosyltransferase (GT).
[0073] Therefore, in the following examples, the screened feruloyl-CoA 6'-hydroxylase mutant was introduced into Escherichia coli, which further increased the yield of scopoletin and provided a reference for the microbial synthesis of coumarin compounds.
[0074] Example 1: Scopoletin synthesis engineering bacteria and construction method thereof
[0075] This embodiment provides a scopoletin synthesis engineering strain BW2: BW1 (pZE-F6'H-COSY, pCS-TAL-FreHpaBC-COMT-4CL), and the construction method of the strain mainly includes the following steps:
[0076] First, tyrosine ammonia lyase TAL, p-coumaroyl-CoA ligase 4CL, flavin reductase Fre, p-hydroxyphenylacetic acid-3-hydroxylase HpaBC, caffeic acid methoxytransferase COMT, feruloyl-CoA 6'-hydroxylase F6'H from Arabidopsis thaliana, and coumarin synthase COSY from Arabidopsis thaliana were selected for PCR amplification to obtain the corresponding gene fragments, and then the fragments and vectors were double-digested with nucleases, and the digested fragments were recovered by gel or column. After that, the target genes were inserted into plasmids pZE12-luc (high copy) and pCS27 (medium copy), respectively, to obtain pZE-F6'H-COSY and pCS-TAL-FreHpaBC-COMT-4CL recombinant plasmids (Table 3), respectively. Among them, the recombinant plasmid pZE-F6'H-COSY is mainly obtained by connecting the genes encoding F6'H and COSY to the vector plasmid pZE12-luc; the recombinant plasmid pCS-TAL-FreHpaBC-COMT-4CL is mainly obtained by connecting the genes encoding TAL, 4CL, FreHpaBC and COMT to the same vector plasmid pCS27.
[0077] Prepare competent cells of recombinant Escherichia coli BW1 by electroporation, and dispense 100 μL into 1.5 mL EP tubes for transformation. Add 2 μL of the constructed recombinant plasmid pZE-F6'H-COSY and 2 μL of pCS-TAL-FreHpaBC-COMT-4CL to a 1.5 mL centrifuge tube containing 100 μL competent cells and mix well. Then use an electroporator to electroporate the plasmid into the competent cells. After electroporation, add LB medium and transfer the mixture to a 1.5 mL centrifuge tube for recovery for about 45 minutes. Then apply the bacterial solution to a plate containing the antibiotics ampicillin and kanamycin, and culture overnight at 37°C to prepare the above-mentioned scopoletin synthesis engineering strain BW2.
[0078] Example 2: Construction of F6'H pocket mutant of feruloyl-CoA 6'-hydroxylase
[0079] In this example, based on the wild-type Arabidopsis thaliana-derived feruloyl-CoA 6'-hydroxylase F6'H gene (accession number NP_187970.1), the amino acid sequence shown in SEQ ID NO.1 was mutated to obtain a feruloyl-CoA 6'-hydroxylase F6'H mutant with higher catalytic activity and stability. The design and construction screening method of the feruloyl-CoA 6'-hydroxylase F6'H pocket mutant is as follows:
[0080] (1) Determine the transformation site and expand the mutant library
[0081] Step 1, based on the crystal structure of feruloyl-CoA 6'-hydroxylase F6'H (PDB: 4XAE), the enzyme is docked with feruloyl-CoA to predict the catalytic site and substrate binding site of the wild-type enzyme. In this embodiment, all molecular dockings are performed using AutoDock software, and related operations are also performed according to the official operating guide of the software;
[0082] Step 2: Analyze the docking results using Pymol software, mainly analyzing the role of amino acid residues in the active pocket of the enzyme, so as to design the amino acid sequence of the mutant;
[0083] Step 3: Search for potential modification sites to further expand the mutant library.
[0084] The final modification sites were determined to be: L141, Q144 and N311, and a mutation library was designed around these three sites.
[0085] (2) Construction of a library of F6'H pocket mutants of feruloyl-CoA 6'-hydroxylase
[0086] Plasmid pZE12-4CL was used as a template for subsequent PCR, wherein the plasmid was mainly obtained by connecting the gene encoding 4CL to the vector plasmid pZE12-luc.
[0087] Step 1, design primers using the target sequence as a template, as shown in Table 5;
[0088] Step 2, using high-fidelity Prime Star enzyme, point mutations were introduced by inverse PCR;
[0089] Step 3, digest the template plasmid DNA with DpnI enzyme;
[0090] Step 4, self-circularize the product obtained in step 3 using a seamless cloning kit;
[0091] Step 5, transformation, introducing the obtained cyclized product into E. coli DH5α competent cells;
[0092] Step 6, pick a single colony and inoculate it into 4 mL of LB medium with corresponding resistance, culture it in a constant temperature shaker at 37° C. and 220 rpm overnight, extract the plasmid and sequence it, and screen out the pZE-F6'H-4CL mutant recombinant plasmid.
[0093] Table 5 Primer sequences used for the construction of feruloyl-CoA 6'-hydroxylase F6'H pocket mutants
[0094]
[0095] Table 5 lists the primers for single mutations of all mutation sites, wherein the double mutants and multiple mutants are obtained by further mutations based on the single mutant L141N, specifically, the double mutant is obtained by further mutations based on the single mutant L141N, and the triple mutant is obtained by further mutations based on the double mutant. Therefore, the primers for the double mutants and multiple mutants are not repeated.
[0096] Example 3: Screening for high-yield feruloyl-CoA 6'-hydroxylase pocket mutants
[0097] Step 1, construct scopoletin synthesis mutant engineering bacteria BW2': BW1 (pZE-F6'H mutant-COSY, pCS-TAL-FreHpaBC-COMT-4CL). The construction method of the mutant engineering bacteria is basically the same as the construction method of the engineering strain provided in Example 1. The main difference is that: this example uses the F6'H mutant screened in Example 2 to replace the wild type F6'H in the recombinant plasmid pZE-F6'H-COSY in Example 1, and the rest remains unchanged.
[0098] Step 2: streak the scopoletin synthesis mutant engineered strain BW2' obtained in step 1 on an LB plate medium with corresponding resistance, then pick a single colony to 4 mL and add it to the corresponding resistance LB medium, culture it overnight at 37°C and 220 rpm in a constant temperature shaker, and then transfer it to 50 mL of fermentation medium until the final OD 600 The induction agent IPTG was added to the sample, and then the sample was cultured in a constant temperature shaker at 33°C and 220 rpm for 72 hours. Finally, 1 mL of the fermentation sample was taken and centrifuged at 12000 rpm for 10 min. The upper layer of liquid was filtered through a 0.22 μm filter membrane into a sample injection bottle and tested by HPLC. The test results are shown in Table 6 and Figure 2 shown.
[0099] Table 6 The yield of scopoletin synthesized by feruloyl-CoA 6'-hydroxylase and its mutants
[0100] Feruloyl-CoA 6'-hydroxylase mutation site Yield (mg / L) Increased compared to wild type wild type 3.1 -- L141N 9.9 3.2 times Q144D 10.2 3.3 times N311G 11.2 3.6 times L141N-Q144D 28.9 9.3 times Q144D-N311G 27.4 8.8 times L141N-N311G 25.6 8.3 times L141N-Q144D-N311G 43.2 13.9 times
[0101] From Table 6 and Figure 2 It can be seen that: using feruloyl-CoA 6'-hydroxylase F6'H L141N-Q144D-N311GThe scopoletin synthesis engineering bacteria constructed by the mutants had the best effect, with a scopoletin yield of 43.2 mg / L, which was 13.9 times higher than the 3.1 mg / L of the initial scopoletin synthesis engineering bacteria strain using the wild type F6'H. Other better mutants included single mutants L141N, Q144D, N311G, and double mutants L141N-Q144D, Q144D-N311G, and L141N-N311G, which were 3.3-9.3 times higher than the wild type. Therefore, the high-yield strain BW20' of the scopoletin synthesis mutant engineering strain BW2' is BW1(pZE-F6'H L141N -Q144D-N311G -COSY, pCS-TAL-FreHpaBC-COMT-4CL).
[0102] Example 4 Application of Feruloyl-CoA 6'-Hydroxylase Pocket Mutant in the Synthesis of Fraxin
[0103] (1) Method for constructing engineered bacteria for synthesizing quercetin and its mutant engineered bacteria
[0104] This embodiment provides a quercetin synthesis engineering bacterium BW3: BW2 (pZE-S8H), which is equivalent to BW1 (pZE-F6'H-COSY-S8H, pCS-TAL-FreHpaBC-COMT-4CL).
[0105] This embodiment also provides a mutant engineering bacterium for synthesizing quercetin BW3': BW2' (pZE-S8H), which is equivalent to BW1 (pZE-F6'H L141N-Q144D-N311G -COSY-S8H, pCS-TAL-FreHpaBC-COMT-4CL). The construction method of the quercetin synthetic mutant engineering bacteria is basically the same as the construction method of the engineering strain provided in Example 1. First, the recombinant plasmid pZE-F6'H L141N-Q144D-N311G -COSY-S8H and pCS-TAL-FreHpaBC-COMT-4CL, among which, the recombinant plasmid pZE-F6'H L141N-Q144D-N311G -COSY-S8H mainly encodes F6'H L141N-Q144D-N311G , COSY and S8H genes were connected to the same vector plasmid pZE12-luc to obtain; then the recombinant plasmid pZE-F6'H L141N-Q144D-N311G -COSY-S8H and pCS-TAL-FreHpaBC-COMT-4CL were electroporated into competent cells of Escherichia coli BW1 to construct the mutant engineering bacteria BW3': BW1 (pZE-F6'H L141N-Q144D-N311G -COSY-S8H, pCS-TAL-FreHpaBC-COMT-4CL).
[0106] (2) Synthesis of quercetin by adding scopolamine in vitro
[0107] The above-mentioned quercetin synthetic mutant engineered bacteria BW3' constructed in this example were streaked and cultured on LB plate culture medium with corresponding resistance, and single colonies were picked from the corresponding plates and added to 4 mL of liquid LB with resistance, and cultured at 37°C for 10 hours, and then the bacterial liquid was transferred to 50 mL of fermentation medium, and 50 mg / L scopoletin was added to the fermentation medium, and 0.5 mM IPTG was added for induction. After that, samples were taken at 24, 48, and 72 hours, and the concentrations of intermediates and target products were determined by high-performance liquid chromatography. The results are as follows: Figure 3 Among them, COSY in the quercetin synthesis mutant engineering bacteria BW3' is derived from Arabidopsis thaliana, Solanum tuberosum, and Glycine max, and the corresponding strains are denoted as the quercetin synthesis mutant engineering bacteria BW30', BW31', and BW32'.
[0108] from Figure 3 It can be seen that under the same conditions, the COSY-derived quercetin-synthesizing mutant engineered bacteria BW30' derived from Arabidopsis thaliana has the highest yield of quercetin, and the yield can reach 50.1 mg / L within 72 hours.
[0109] (3) De novo synthesis of quercetin using simple carbon sources
[0110] Using a simple carbon source as the source, the de novo synthesis of quercetin was achieved using the quercetin synthesis mutant engineered bacteria BW30'. Compared with the synthesis of quercetin by adding scopolamine in vitro, the main difference is that no additional scopolamine is added to the fermentation medium used in the de novo synthesis of quercetin, and the other process methods are the same. Among them, the fermentation situation of de novo synthesis of quercetin using the quercetin synthesis mutant engineered bacteria BW30' is shown in the figure. Figure 4 shown.
[0111] from Figure 4 It can be seen that: using feruloyl-CoA 6'-hydroxylase F6'H L141N-Q144D-N311G In the mutant quercetin synthesis engineering bacteria BW30', the quercetin production reached 52.2 mg / L after 72 hours of fermentation.
[0112] Example 5 Application of Feruloyl-CoA 6'-Hydroxylase Pocket Mutant in the Synthesis of Fraxinoside
[0113] (1) Method for constructing engineered bacteria for the synthesis of quercetin and its mutant engineered bacteria
[0114] This embodiment provides a quercetin synthesis engineering bacterium BW4: BW1 (pZE-F6'H-COSY-UGT71E1-S8H, pCS-TAL-FreHpaBC-COMT-4CL); which is equivalent to BW4 (pZE-UGT71E).
[0115] This embodiment also provides a mutant engineering bacterium BW4': BW1 (pZE-F6'H L141N-Q144D-N311G -COSY-UGT71E-S8H, pCS-TAL-FreHpaBC-COMT-4CL), which is equivalent to BW3'(pZE-UGT71E). The construction method of the quercetin synthesis mutant engineering bacteria is basically the same as the construction method of the engineering strain provided in Example 1. First, the recombinant plasmid pZE-F6'H L141N-Q144D-N311G -COSY-UGT71E-S8H and pCS-TAL-FreHpaBC-COMT-4CL, among which, the recombinant plasmid pZE-F6'H L141N-Q144D-N311G -COSY-UGT71E-S8H mainly converts the code F6'H L141N-Q144D-N311G , COSY, UGT71E and S8H genes were connected to the same vector plasmid pZE12-luc to obtain; then the recombinant plasmid pZE-F6'H L141N-Q144D-N311G -COSY-UGT71E1-S8H and pCS-TAL-FreHpaBC-COMT-4CL were electroporated into competent cells of Escherichia coli BW1 to construct the mutant engineering bacteria BW4': BW1 (pZE-F6'H L141N-Q144D-N311G -COSY-UGT71E-S8H, pCS-TAL-FreHpaBC-COMT-4CL); further, in this embodiment, the mutant engineering bacteria BW4' is equivalent to BW30' (pZE-UGT71E).
[0116] (2) Synthesis of quercetin by adding quercetin in vitro
[0117] The method for synthesizing quercetin using the above-mentioned quercetin-synthesizing mutant engineered bacteria BW4' in this example is basically the same as the method for synthesizing quercetin using the engineered bacteria BW3' in Example 4 "(2) Synthesis of quercetin by adding scopoletin in vitro", the main difference being that 50 mg / L of quercetin is added in this example to replace the scopoletin added in Example 4, and the other process methods are the same; the fermentation results of the engineered bacteria BW4' with different quercetin-8-O-glycosyltransferases are shown in Figure 4. Figure 5As shown. Among them, the quercetin synthesis mutant engineering bacteria BW4' in this embodiment is BW30'(pZE-UGT71E), and the quercetin-8-O-glycosyltransferases therein are UGT71E1, UGT71E2, and UGT71E3, respectively, and the corresponding strains are respectively represented as quercetin synthesis mutant engineering bacteria BW40', BW41', and BW42'.
[0118] from Figure 5 It can be seen that under the same conditions, the quercetin-8-O-glycosyltransferase UGT71E1 mutant engineering bacteria BW40' has the highest yield of quercetin, and the yield can reach 107.2 mg / L within 72 hours.
[0119] (3) De novo synthesis of quercetin using simple carbon sources
[0120] Using a simple carbon source as the source, the de novo synthesis of quercetin was achieved using the quercetin synthesis mutant engineered bacteria BW40'. Compared with the synthesis of quercetin by adding quercetin in vitro, the main difference is that no additional quercetin is added to the fermentation medium used in the de novo synthesis of quercetin, and the other process methods are the same. Among them, the fermentation situation of the de novo synthesis of quercetin using the quercetin synthesis mutant engineered bacteria BW40' is shown in the figure. Figure 6 shown.
[0121] from Figure 6 It can be seen that: using feruloyl-CoA 6'-hydroxylase F6'H L141N-Q144D-N311G In the mutant quercetin synthesis engineering bacteria BW40', the quercetin production reached 115.7 mg / L after 72 hours of fermentation.
[0122] Example 6 Application of Feruloyl-CoA 6'-Hydroxylase Pocket Mutant in the Synthesis of Scopoletin
[0123] (1) Method for constructing scopoletin synthesis engineering bacteria and mutant engineering bacteria
[0124] This embodiment provides a scopoletin synthesis engineering bacterium BW5: BW1 (pZE-F6'H-COSY-GT, pCS-TAL-FreHpaBC-COMT-4CL); which is equivalent to BW2 (pZE-GT).
[0125] This embodiment also provides a scopoletin synthesis mutant engineering bacteria BW5': BW1 (pZE-F6'H L141N-Q144D-N311G -COSY-GT, pCS-TAL-FreHpaBC-COMT-4CL), which is equivalent to BW2'(pZE-GT). The construction method of the scopoletin synthesis mutant engineering bacteria is basically the same as the construction method of the engineering strain provided in Example 1. First, the recombinant plasmid pZE-F6'H L141N-Q144D-N311G-COSY-GT and pCS-TAL-FreHpaBC-COMT-4CL, among which, the recombinant plasmid pZE-F6'H L141N-Q144D-N311G -COSY-GT is mainly obtained by connecting the genes encoding F6'H / (L141N-Q144D-N311G), COSY and GT to the same vector plasmid pZE12-luc; then the recombinant plasmid pZE-F6'H L141N-Q144D-N311G -COSY-GT and pCS-TAL-FreHpaBC-COMT-4CL were electroporated into competent cells of Escherichia coli BW1 to construct scopoletin synthesis mutant engineering bacteria BW5': BW1 (pZE-F6'H L141N-Q144D-N311G -COSY-GT, pCS-TAL-FreHpaBC-COMT-4CL).
[0126] (2) Synthesis of scopoletin by adding scopolamine in vitro
[0127] The method for synthesizing scopolamine using the above-mentioned scopolamine synthesis mutant engineered bacteria BW5' in this example is basically the same as the method for synthesizing scopolamine using the engineered bacteria BW3' in Example 4 "(2) Synthesis of scopolamine by adding scopolamine in vitro", with the main difference being that the engineered bacteria BW5' is used as the strain in this example, and the other process methods are the same; the fermentation results of the engineered bacteria BW5' with different scopolamine-7-O-glycosyltransferases are shown in Figure 2. Figure 7 As shown. Among them, the scopoletin synthesis mutant engineering bacteria BW5' in this embodiment is BW2'(pZE-GT), and the scopoletin-glycosyltransferase GT therein are TOGT1, TOGT2, UGT71E1, UGT71E2, UGT71E3, and the corresponding strains are respectively represented as scopoletin synthesis mutant engineering bacteria BW50', BW51', BW52', BW53', BW54'.
[0128] from Figure 7 It can be seen that under the same conditions, the scopoletin synthesis mutant engineering bacteria BW50' with scopoletin-glycosyltransferase TOGT1 has the highest yield of scopoletin synthesis, and the yield can reach 102.4 mg / L within 72 hours.
[0129] (3) De novo synthesis of scopolamine using simple carbon sources
[0130] Using a simple carbon source as the source, the de novo synthesis of quercetin was achieved using the quercetin synthesis mutant engineered bacteria BW40'. Compared with the synthesis of scopolamine by adding scopolamine in vitro, the main difference is that no additional scopolamine is added to the fermentation medium used in the de novo synthesis of scopolamine, and the other process methods are the same. Among them, the fermentation situation of the de novo synthesis of quercetin using the scopolamine synthesis mutant engineered bacteria BW40' is shown in the figure. Figure 8shown.
[0131] from Figure 8 It can be seen that: using feruloyl-CoA 6'-hydroxylase F6'H L141N-Q144D-N311G In the mutant scopolamine synthesis engineering bacteria BW50', the scopolamine production reached 82.9 mg / L after 72 hours of fermentation.
[0132] Therefore, the engineered bacteria constructed using the feruloyl-CoA 6'-hydroxylase mutant provided in the embodiment of the present invention have the advantages of high yield and a wide variety of coumarin compounds, which is conducive to industrialized production and reduces production costs, and provides an important basis for the industrial production of coumarin compounds.
[0133] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, ordinary technicians in the field should understand that the specific implementation methods of the present invention can still be modified or some technical features can be replaced by equivalents without departing from the spirit of the technical solution of the present invention, which should be included in the scope of the technical solution for protection of the present invention.
Claims
1. A feruloyl-CoA 6'-hydroxylase pocket mutant, characterized in that: It is mainly obtained by amino acid mutation of the amino acid sequence shown in SEQ ID NO.1, including at least one of the following amino acid mutations: L141N, Q144D, N311G; Preferably, the amino acid mutation is a double mutation or a triple mutation; more preferably, the amino acid mutation is L141N-Q144D, L141N-Q144D-N311G; Preferably, the feruloyl-CoA 6'-hydroxylase is derived from Arabidopsis thaliana Arabidopsis thaliana .
2. A gene encoding the feruloyl-CoA 6'-hydroxylase pocket mutant according to claim 1.
3. A recombinant plasmid, characterized in that: It is connected to the gene according to claim 2; Preferably, the recombinant plasmid comprises pZE12-luc, pCS27 or pSA74.
4. An engineered bacterium for synthesizing coumarin compounds, characterized in that: A host bacterium and the recombinant plasmid according to claim 3 transformed into the host bacterium; Preferably, the coumarin compound is scopoletin, scopolamine, fraxinin or fraxinin; Preferably, the host bacteria are original bacteria or fungi, or modified bacteria or fungi; More preferably, the host bacteria is Escherichia coli BW25113 or recombinant Escherichia coli BW25113ΔpykA / F::aroG fbr ::tyrA fbr .
5. The engineered bacteria according to claim 4, characterized in that: The recombinant plasmid is also connected with genes encoding tyrosine ammonia lyase, flavin reductase, p-hydroxyphenylacetic acid-3-hydroxylase, caffeic acid methoxytransferase, p-coumaroyl-CoA ligase and coumarin synthase; Preferably, the coumarin synthase is derived from Arabidopsis thaliana A. thaliana ,potato Solanum tuberosum or soybean Glycine max ; Preferably, the tyrosine ammonia lyase is derived from Rhodobacter sphaeroides Rhodobacter sphaeroides , Rhodotorula R. glutinis , Streptomyces albus Streptomyces albus , Rhodobacter capsulatus R Hodobacter capsulatus Micromonospora aculeatus Micromonospora echinofusca The p-coumaryl-CoA ligase is derived from Arabidopsis thaliana Arabidopsis thaliana or parsley Petroselinum crispum , the flavin reductase is derived from Escherichia coli Escherichia coli , the p-hydroxyphenylacetate-3-hydroxylase is derived from Klebsiella Klebsiella pneumonia , the caffeic acid methoxytransferase is derived from Arabidopsis thaliana Arabidopsis thaliana .
6. The engineered bacteria according to claim 5, characterized in that: The recombinant plasmid is also connected with a gene encoding scopoletin-glycosyltransferase; Preferably, the scopoletin-glycosyltransferase is derived from tobacco Nicotiana tabacum Arabidopsis thaliana Arabidopsis thaliana .
7. The engineered bacteria according to claim 5, characterized in that: The recombinant plasmid is also connected with a gene encoding scopoletin-8-hydroxylase; Preferably, the scopoletin-8-hydroxylase is derived from Arabidopsis thaliana Arabidopsis thaliana .
8. The engineered bacteria according to claim 7, characterized in that: The recombinant plasmid is also connected to a gene encoding fraxin-8-O-glycosyltransferase; Preferably, the fraxin-8-O-glycosyltransferase is derived from Arabidopsis thaliana Arabidopsis thaliana .
9. A method for biosynthesis of coumarin compounds, comprising: The step of inoculating the engineered bacteria according to any one of claims 4 to 8 into a fermentation medium at an inoculation volume fraction of 1% to 10% for fermentation culture to obtain coumarin compounds; Preferably, the inoculation amount is 2% to 5%, and the fermentation temperature is 30°C to 40°C; Preferably, the fermentation medium comprises: 0.5-1.5 g / L FeSO4, 1-5 g / L MOPS, 5-20 g / L carbon source, 1-5 g / L yeast powder, 5-8 g / L Na2HPO4, 0.3-2 g / L NaCl, 2.3-4.0 g / L KH2PO4 and 1-5 g / L NH4Cl.
10. The synthesis method according to claim 9, characterized in that: The step also includes first adding an intermediate compound to the fermentation medium, and then fermenting and culturing the engineered bacteria; Preferably, the intermediate compound is at least one of tyrosine, p-coumaric acid, caffeic acid, ferulic acid, scopoletin and fraxinusin.
Citation Information
Patent Citations
Method for heterologous biosynthesis of tonquinol, caffeol and ferulenol
CN105907804A
Enzymatic preparation method of scopoletin
CN115927500A
Engineering Bacteria for Ferulic Acid Production, Preparation Method and Use Thereof
US20220049235A1
Recombinant yeast capable of producing caffeic acid and / or ferulic acid
US20220372431A1
Cited By
Application of divaricate saposhnikovia root SdC2 'H gene and method for increasing coumarin content in divaricate saposhnikovia root by using same
CN120866338A
